| |
Three
Months Ended |
Year
ended |
Particulars |
30.06.2002 |
30.06.2001 |
31.03.2002 |
| |
(Unaudited) |
(Unaudited) |
(Audited) |
| Net Sales/Income from Operations |
2472.4 |
1889.2 |
10377.2 |
| Other Income |
31.8 |
10.4 |
146.8 |
| Total Income |
2504.2 |
1899.6 |
10524.0 |
| Expenditure |
|
|
|
| a. (Increase) / Decrease in Stock in
Trade |
(66.2) |
(81.9) |
209.3 |
| b. Consumption of Raw Materials |
1622.1 |
1218.2 |
6671.7 |
| c. Staff Cost |
58.9 |
55.4 |
251.7 |
| d. Other Expenditure |
520.2 |
438.6 |
2020.9 |
| Total expenditure |
2135.0 |
1630.3 |
9153.6 |
| Profit Before Depreciation, Interest
& Tax |
369.2 |
269.3 |
1370.4 |
| Interest |
128.0 |
110.1 |
423.9 |
| Depreciation |
39.3 |
36.5 |
158.1 |
| Profit before extra-ordinary item
& taxation |
201.9 |
122.7 |
788.4 |
| Add: Extra-ordinary item |
- |
- |
100.0 |
| Profit after extra ordinary item &
before taxation |
201.9 |
122.7 |
888.4 |
| Provision for Taxation |
|
|
|
| a. Current Tax |
45.0 |
10.0 |
153.7 |
| b. Deferred Tax |
6.0 |
- |
37.9 |
| c. Tax adjustments of previous years |
- |
- |
117 |
| Net Profit |
150.9 |
112.7 |
685.1 |
| Paid-up Equity Share Capital |
222.0* |
202.0 |
206.7 |
| (Face value Rs. 10 per share) |
|
|
|
| Reserves excluding Revaluation Reserves |
- |
- |
3406.9 |
| Basic Earnings per Share (in Rs.) (not
annualised) |
6.86 |
5.58 |
33.89 |
| Diluted Earnings per share (Rs.) |
6.86 |
- |
33.89 |
| Aggregate of Non-promoters Shareholding |
|
|
|
| a. Number of Shares |
7,963,498 |
7,402,960 |
6,978,167 |
| b. Percentage of Shareholding |
35.87 |
37.01 |
33.76 |
|
| Notes: |
| 1. |
The
above unaudited results were taken on record by the Board at its meeting held on
31.07.2002. |
| 2. |
The Company allotted 15,30,000 equity shares
of Rs.10/- each at a premium of Rs.216/- and equal number of share warrants by way
of preferential issue on private placement basis during the period |
| 3. |
Figures
for the previous quarter have been rearranged wherever necessary. |
|
|
|
|
|
For and on behalf of the Board |
|
| Place: Hyderabad |
|
K.Nityananda Reddy |
| Date : 31.07.2002 |
|
Managing Director |
|
|
|
|
Aurobindo Pharma Limited |
|
Segment
wise Revenue, Results and Capital employed |
|
under
clause 41 of the Listing Agreement |
| |
Quarter Ended |
Year Ended |
|
Particulars |
30.06.2002 |
31.03.2002 |
| |
(Unaudited)
|
(Audited) |
|
1. Segment Revenue |
|
|
| a. Bulk Drugs & Drug Intermediaries
|
2423.2 |
10855.9 |
| b. Formulation |
143.2 |
1061.7 |
| c. Research & Development |
0 |
0 |
| Total |
2566.4 |
11917.6 |
| Less: Inter segment revenue |
79.9 |
(1433.0) |
|
Net Sales/Income from operation |
2486.5 |
10484.6 |
|
2. Segment Results Profit(+) / Loss(-)
before tax and interest |
|
|
| a. Bulk Drugs & Drug Intermidiaries |
362.2 |
1444.6 |
| b. Formulations |
11.2 |
227.8 |
| c. Research & Development |
(18.9) |
(60.5) |
| Total |
354.5 |
1611.9 |
| Less: (i) Interest (Net)
|
120.8 |
392.6 |
|
(ii) Other un-allocable expenditure |
31.8 |
330.9 |
| net of unallocable income |
|
|
|
Total Profit before tax |
201.9 |
888.4 |
|
3. Capital Employed |
|
|
| a. Bulk Drugs |
4189.3 |
3870.9 |
| b. Formulation |
1190.8 |
1180.0 |
| c. Research & Development |
179.7 |
173.9 |
|
Total |
5559.8 |
5224.8 |
|
|
|
|
|
